Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ling Pan

Showing results (661-670 of 663) with videos related to

Pageof 67
Sort By:
You have reached the last page of results.This site can display upto 663 results.
BMC Cancer|October 14, 2023
Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trialZhongjun Xia, Yun Leng, Baijun Fang, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|July 28, 2025
Chinese expert consensus on hematologic malignancy karyotypingZailin Yang, Shuang Chen, Mingyu Zhao, et al.
American Journal of Hematology|May 2, 2023
Imatinib compared with second-generation tyrosine kinase-inhibitors in persons with chronic myeloid leukemia presenting in accelerated phaseSen Yang, Xiaoshuai Zhang, Robert Peter Gale, et al.
Pageof 67

Showing results (661-670 of 663) with videos related to

Sort By:
Pageof 67
You have reached the last page of results.This site can display upto 663 results.
BMC Cancer|October 14, 2023
Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trialZhongjun Xia, Yun Leng, Baijun Fang, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|July 28, 2025
Chinese expert consensus on hematologic malignancy karyotypingZailin Yang, Shuang Chen, Mingyu Zhao, et al.
American Journal of Hematology|May 2, 2023
Imatinib compared with second-generation tyrosine kinase-inhibitors in persons with chronic myeloid leukemia presenting in accelerated phaseSen Yang, Xiaoshuai Zhang, Robert Peter Gale, et al.
Pageof 67